Verrica Pharmaceuticals VRCA Income Statement (2017-2026)

NASDAQ VRCA
$4.86 -0.13 (-2.61%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
0.43M0.21M8.32M0.07M0.04M0.18M2.92M1.99M3.83M5.18M1.78M0.34M3.44M12.70M14.34M5.09M5.02M5.86M
Operating items
Research & Development (Quarter)
3.76M-10.27M2.44M3.94M2.78M3.03M2.74M5.72M6.51M5.32M4.95M3.32M2.40M1.17M2.28M1.85M2.21M2.52M3.86M6.03M
Selling, General & Administrative (Quarter)
8.01M5.11M5.12M5.17M3.92M3.19M4.32M5.94M20.05M17.00M16.34M16.52M16.08M9.88M8.85M8.85M9.40M8.12M9.99M10.35M
Other Operating Expenses (Quarter)
13.63M0.28M0.22M0.17M0.06M0.07M0.14M0.27M2.81M1.14M0.54M0.43M0.71M0.44M0.49M1.11M1.65M0.89M-1.70M
Operating Expenses (Quarter)
11.77M8.47M7.84M9.34M6.87M6.28M7.13M11.80M26.83M25.12M22.43M20.38M18.92M11.75M11.57M11.19M12.72M12.28M14.74M18.96M
Operating Income (Quarter)
-11.77M-8.47M-7.41M-9.12M1.45M-6.21M-7.09M-11.62M-23.92M-23.14M-18.60M-15.21M-20.70M-11.41M-8.13M1.51M1.63M-7.19M-9.71M-13.10M
EBIT (Quarter)
-11.77M-8.47M-7.41M-9.12M1.45M-6.21M-7.09M-11.62M-23.92M-23.14M-18.60M-15.21M-20.70M-11.41M-8.13M1.51M1.63M-7.19M-9.71M-13.10M
Non-operating items
Interest & Investment Income (Quarter)
0.03M0.03M0.02M0.02M0.15M0.29M0.50M0.63M0.82M0.79M0.60M0.39M0.22M0.20M0.34M0.23M0.16M0.20M0.20M0.11M
Other Non Operating Income (Quarter)
-0.00M-1.44M-1.39M-0.05M0.05M-0.01M-2.63M0.25M0.60M2.65M-0.01M-0.00M
Non Operating Income (Quarter)
-1.06M-1.07M-1.06M-1.05M-1.36M0.28M0.50M0.63M-0.89M-1.48M-1.73M-1.98M-2.16M-4.79M-1.61M-1.31M-1.90M-0.88M0.03M-0.06M
Net income details
EBT (Quarter)
-12.84M-10.63M-8.47M-10.48M1.50M-6.31M-10.89M-10.99M-24.75M-24.18M-2706.93M-17.18M-30.93M-12.94M-10.00M-1.17M-4.09M-10.38M-10.54M-14.51M
Profit After Tax (Quarter)
-12.83M-9.57M-8.47M-10.17M0.08M-5.90M-6.59M-10.99M-24.80M-24.61M-20.33M-17.19M-22.86M-16.20M-9.74M0.20M-0.27M-8.07M-9.68M-13.15M
Income from Non-Controlling Interests (Quarter)
-0.00M-0.03M-0.03M-0.00M0.04M0.03M
Income from Continuing Operations (Quarter)
-12.84M-10.63M-8.47M-10.48M1.50M-6.31M-10.89M-10.99M-24.75M-24.18M-2706.93M-17.18M-30.93M-12.94M-10.00M-1.17M-4.09M-10.38M-10.54M-14.51M
Consolidated Net Income (Quarter)
-12.84M-10.63M-8.47M-10.48M1.50M-6.31M-10.89M-10.99M-24.75M-24.18M-2706.93M-17.18M-30.93M-12.94M-10.00M-1.17M-4.09M-10.38M-10.54M-14.51M
Income towards Parent Company (Quarter)
-12.84M-10.63M-8.47M-10.48M1.50M-6.31M-10.89M-10.99M-24.75M-24.18M-2706.93M-17.18M-30.93M-12.94M-10.00M-1.17M-4.09M-10.38M-10.54M-14.51M
Net Income towards Common Stockholders (Quarter)
-12.84M-10.63M-8.47M-10.48M0.08M-6.31M-10.89M-10.99M-24.80M-24.18M-2706.93M-17.19M-30.93M-12.94M-10.00M0.20M-4.09M-10.38M-10.54M-14.51M
Additional items
EPS (Basic) (Quarter)
-4.67-3.93-3.08-3.810.02-1.85-2.53-2.39-5.38-5.33-582.34-3.70-6.61-2.50-1.050.02-0.43-0.97-0.49-0.68
EPS (Diluted) (Quarter)
-4.67-3.93-3.08-3.810.02-1.85-2.53-2.39-5.38-5.33-582.34-3.70-6.61-2.50-1.050.02-0.43-0.97-0.49-0.68
Shares Outstanding (Quarter)
2.75M2.70M2.75M2.75M4.03M3.42M4.30M4.59M4.61M4.53M4.65M4.65M4.68M5.18M9.48M9.49M9.49M10.65M21.31M21.31M
Shares Outstanding (Diluted) (Quarter)
2.75M2.70M2.75M2.75M4.47M3.42M4.30M4.59M4.61M4.53M4.65M4.65M4.68M5.18M9.48M9.49M9.49M10.65M21.31M21.31M
Shares Outstanding (Entity) (Quarter)
2.76M2.75M2.76M2.76M4.12M3.42M4.20M4.20M4.22M4.25M4.25M4.26M4.57M5.18M9.19M9.27M9.50M10.65M17.19M17.19M
EBITDA (Quarter)
-11.77M-8.47M-7.41M-9.12M1.45M-6.21M-7.09M-11.62M-23.92M-23.14M-18.60M-15.21M-20.70M-11.41M-8.13M1.51M1.63M-7.19M-9.71M-13.10M
Interest Expenses (Quarter)
1.10M2.18M1.08M1.38M0.10M0.38M4.30M1.66M1.83M2,688.93M2.37M10.45M1.73M2.20M2.91M5.88M3.39M1.03M1.52M